Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals Limited has appointed Dr. Patricia Walker to its Board of Directors, bringing her extensive experience in dermatology and drug development to the company. Dr. Walker’s appointment is expected to enhance Botanix’s product development and strategic direction, leveraging her expertise in securing corporate financing and evaluating potential product acquisitions. Her previous work with leading dermatology companies and her role in developing Botanix’s lead product, Sofdra™, positions her as a valuable asset to the company’s future growth and innovation.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.27 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, US. The company focuses on developing innovative dermatological treatments and has received FDA approval for its lead product, Sofdra™, which treats primary axillary hyperhidrosis. Sofdra™ is notable for being the first and only new chemical entity approved by the FDA for this condition, offering a novel and effective solution for patients.
Average Trading Volume: 15,306,475
Technical Sentiment Signal: Sell
Current Market Cap: A$294.2M
Learn more about BOT stock on TipRanks’ Stock Analysis page.